Stock ABUS ARBUTUS BIOPHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
2.98 USD +3.11% Intraday chart for Arbutus Biopharma Corporation +1.36% +19.20%
May. 17 Sector Update: Health Care Stocks Mixed Late Afternoon MT
May. 17 Sector Update: Health Care Stocks Softer Friday Afternoon MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
Sector Update: Health Care Stocks Softer Friday Afternoon
MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
MT
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
BU
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner
RE
Whitefort Capital Management Engages with Arbutus Biopharma
CI
Arbutus to Participate in Two Upcoming Investor Conferences
GL
Arbutus Biopharma : Corporate Presentation - May 2024
PU
Transcript : Arbutus Biopharma Corporation, Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M
MT
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M
MT
Arbutus: Q1 Earnings Snapshot
AQ
Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
GL
Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024
CI
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
GL
Arbutus Biopharma : Corporate Presentation - April 2024
PU
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABUS Stock
  4. News Arbutus Biopharma Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW